This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Merck (MRK) is Outperforming Its Industry Of Late
by Zacks Equity Research
Merck's shares are up 11.9% this year so far on strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.
AstraZeneca's Farxiga Gets Fast Track Tag for Renal Outcome
by Zacks Equity Research
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to delay progression of renal failure and prevent cardiovascular and renal death in patients with chronic kidney disease.
Inovio (INO) Down More Than 30% in 3 Months: Here's Why
by Zacks Equity Research
Inovio (INO) stops the development of INO-5401 for advanced bladder cancer, and cuts workforce by 28% and annual burn rate by 25% as part of the restructuring process.
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
by Kinjel Shah
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
by Zacks Equity Research
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
by Kinjel Shah
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
by Zacks Equity Research
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
by Zacks Equity Research
Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.
Agios Rides High on Tibsovo Sales Amid Acute Competition
by Zacks Equity Research
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
by Zacks Equity Research
Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.
AVEO Pharmaceuticals (AVEO) Q2 Earnings Beat, Revenues Lag
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss is narrower than expected in the second quarter of 2019. However, revenues fall short of estimates.
Inovio (INO) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Inovio Pharmaceuticals (INO) disappoints with earnings and revenue miss in the second quarter. Shares depreciate in after-hours trading.
Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.
Merck (MRK) Beats on Q2 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Merck (MRK) beats estimates for earnings as well as sales in second-quarter 2019. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand. Shares up.
AstraZeneca (AZN) Jumps: Stock Rises 5.7%
by Zacks Equity Research
AstraZeneca (AZN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment
by Kinjel Shah
AstraZeneca (AZN), Roche (RHHBY), Bristol-Myers (BMY) and Glaxo (GSK) report Q2 results. FDA approves Lilly's (LLY) nasal glucagon to treat severe hypoglycemia.
AstraZeneca (AZN) Q2 Earnings Top, '19 Product Sales View Up
by Zacks Equity Research
AstraZeneca (AZN) beats estimates for earnings and sales. New drugs, mainly cancer medicines, lead to high product sales.
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
Inovio (INO) Ends Some Early-Stage R&D Programs, Cuts Jobs
by Zacks Equity Research
Inovio (INO) stops the phase I/II study on INO-5401 for advanced bladder cancer and cuts its workforce by 28% and annual burn rate by 25%. Shares fall in after-hours trading.
Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA
by Zacks Equity Research
Alkermes (ALKS) plans to expand the NDA for ALKS 3831 to include the treatment of bipolar I disorder in addition to the treatment for schizophrenia.
AstraZeneca's Farxiga Gets CRL from FDA for Type I Diabetes
by Zacks Equity Research
AstraZeneca's (AZN) SGLT2 inhibitor, Farxiga, gets CRL from the FDA for a regulatory application seeking label expansion as a treatment for type I diabetes.
Top Stock Reports for Cisco, Home Depot & Merck
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Home Depot (HD) and Merck (MRK).